Insignificant effect of ethanol extract of Dipterocarpus turbinatus (Dipterocarpaceae) bark on selected parameter in alloxan-induced diabetic rats

Biswas, Diptanu; Gouda, Shivraj T; Gowrishankar, Narayanaswamy Lachmanan

doi:10.4103/0976-9234.177059

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, many studies have shown the antimicrobial activity of several extracts and secondary metabolites of plants conventionally used in the traditional medicine, which contributes to the discovery of new bioactive compounds. [21] However, there are no reports in the literature about the phytochemical and antimicrobial activity of T. micrantha to compare and discuss the results obtained in this work.…”

Section: Discussionmentioning

confidence: 84%

Evaluation of the activity of Tontelea micrantha extracts against bacteria, Candida and Mayaro virus

Cruz¹,

Ferraz²,

Lima³

et al. 2018

J Pharm Negative Results

View full text Add to dashboard Cite

The use of antimicrobials represents one of the most successful ways of chemotherapy in the medical clinic. These drugs were responsible for the control of several infectious diseases, which have been considered as the main cause of mortality and morbidity throughout the history of the humanity. [1] However, infectious diseases remain a major challenge to human health. Currently, it is estimated that about 1 billion people are diagnosed with mycoses annually, and more than 1.5 million die from complications of invasive fungal diseases. [2] Furthermore, infectious diarrhea and pneumonia account for 40% of child deaths worldwide, especially in underdeveloped regions. [3] Over the past 40 years, only two classes of antibiotics effective against Gram-negative bacteria have been approved for clinical use (e.g., oxazolidinones and cyclic lipopeptides) and the development of new antimicrobials in the future seems unpromising. [3] Currently, there is a scarce therapeutic arsenal for the treatment of fungal infections and the development of new antifungal drugs conflicts with the difficulty of finding compounds which are specific for fungal cells. [4] Similar situation happens with the development of new antivirals. Since viruses are obligate intracellular parasites, finding a drug that has an action against the virus but does not interfere with the basal functions of the cells is pointed out as the main challenge. [5] In this regard, considering the 15 largest companies in the pharmaceutical industry, only 5 of their drugs in the clinical or preclinical research phase are anti-infective agents. [3] The alarming increase in the microorganism's resistance to the currently available antimicrobials, caused mainly by the long-term exposure to subinhibitory concentrations of these

show abstract

Section: Discussionmentioning

confidence: 84%